Claims

1. A composition for inhibiting enterovirus, wherein the composition includes a first active ingredient and a second active ingredient,

wherein the first active ingredient is an inhibitor of 3D protein of enterovirus (e.g., EV71), which is favipiravir, or a pharmaceutically acceptable salt thereof;

the second active ingredient is an inhibitor of capsid protein of enterovirus (e.g., EV71), which is favipiravir, or a pharmaceutically acceptable salt thereof;

wherein, the first active ingredient specifically binds to amino acid residue at position 121 of 3D protein of enterovirus, wherein the amino acid residue is numbered based on SEQ ID NO: 1.

2. The composition of claim 1, wherein the first active ingredient specifically binds to a serine residue at position 121 of 3D protein of enterovirus, wherein the amino acid residue is numbered based on SEQ ID NO: 1.

3. The composition of claim 1, wherein the molar ratio of the first active ingredient to the second active ingredient is about 10-100: 1-20.

4. The composition of claim 1, wherein the molar ratio of the first active ingredient to the second active ingredient is 10-100: 1-10.

5. The composition of claim 1, wherein the molar ratio of the first active ingredient to the second active ingredient is 10-100: 1-5.

6. Use of the composition for inhibiting enterovirus of claim 1 for the manufacture of the medicament for preventing and/or treating enterovirus infection.

7. A method for non-therapeutically inhibiting enterovirus growth or killing of enterovirus *in vitro* comprising the step of applying the composition for inhibiting enterovirus of claim 1 in a place that needs to be treated.